Lyra Therapeutics Inc (LYRA): Rasio rega marang pendapatan

Simbol lan logo merek Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics, Inc. (LYRA) develops drug delivery systems for ENT organs, though it is currently struggling with a capital shortage following failed tests. The company's rolling P/S ratio helps assess market demand, while 1.40 determines the current status of this parameter. Growth prospects rely on the success of the LYR-210 drug and its potential FDA approval for expansion into the sinus treatment market.

LYRA Rasio rega marang pendapatan lyratherapeutics.com (04.07.2022 - 28.03.2026)

Lyra Therapeutics, Inc. (LYRA) - rincian metrik lan laporan keuangan

Ringkesan analitik perusahaan:Lyra Therapeutics
Produk mawa merek Lyra Therapeutics Inc

For the biotech startup Lyra Therapeutics, Inc. (LYRA), the P/S ratio serves as an indicator of market expectations regarding future revenue streams. This metric is calculated as the ratio of current market capitalization to total annual sales. Analyzing the history of P/S values allows for the identification of asset overvaluation in the absence of a commercial product. In the context of failed clinical trials and restructuring, this indicator highlights the speculative nature of the share price amid scaled-back operations.

Perusahaan pesaing

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals)|Rasio kapitalisasi pasar marang pendapatan BHST|Invizyne Technologies - Multiplikator P/S|oramed.com (ORMP) - Kapitalisasi marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator P/S|Multiplikator P/S cumberlandpharma.com|Rasio rega marang pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Multiplikator rega marang pendapatan|Multiplikator P/S TELO (telomirpharma.com)|RANI - Kapitalisasi marang pendapatan|SNYR - Rasio rega marang pendapatan|rallybio.com - Kapitalisasi marang volume dodolan|LEXX: Multiplikator P/S|Kapitalisasi marang pendapatan Pulmatrix Inc|PTHL (Pheton Holdings) - Multiplikator P/S|Rega marang dodolan Aptorum Group Limited APM|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)